建筑物从英国的基于大麻的药品工厂开始

最近在英国Stietbourne的肯特科学园（KSP）建造了新的60,000平方英尺制造工厂的建设，代表了爵士Pharmaceuticals PLC及其子公司GW Pharmaceuticals的投资超过1亿美元（约7500万英镑）。预计将在运营时创造100多个高技能的新工作，该设施旨在支持该公司的两种基于监管的大麻药物和正在开发的新药物的未来能力。该公司目前在KSP生产提取物，活跃的药品成分和配制的药品，占领了12栋拥有400多名员工的建筑物，该公司表示，英国已成为其全球大麻素制造业务的核心。

设施设计还包括对环境的仔细考虑；将安装动物避难箱以在当地促进野生动植物，将单一使用塑料的使用最小化，并将安装超过1100个太阳能电池板，以提供建筑物的一部分能源使用。

“英国已经成为我们的家已有二十年了。this strategic investment underlines Jazz’s continued commitment to the UK and will help us bring potentially life-changing medicines to more patients who desperately need them in the UK and around the world,” said Chris Tovey, executive vice president, chief operating officer and managing director, Europe & International at Jazz Pharmaceuticals. “We are thrilled to have commenced construction of this state-of-the-art facility in Kent, which will create more than 100 permanent, highly skilled jobs. This facility, which is expected to open in 2024, will not only significantly increase our ability to support the growing demand for our medicines, but help us maintain our position as a world leader in cannabinoid science.”

更多信息在线的